TRT and Blood Pressure: Why Testosterone Can Raise BP and What to Monitor

Blood pressure is now one of the clearest safety checkpoints for men using testosterone replacement therapy. In February 2025, the U.S. Food and Drug Administration announced class-wide testosterone labeling changes after reviewing the TRAVERSE cardiovascular safety trial and postmarket ambulatory blood pressure monitoring studies. The key practical takeaway: FDA said completed ambulatory blood pressure studies confirmed increased blood pressure with testosterone products class-wide, even as TRAVERSE did not show an increased risk of major adverse cardiovascular events in appropriately selected hypogonadal men.

That combination can feel confusing. It does not mean every man on TRT will develop hypertension, and it does not mean testosterone is automatically unsafe for every man with cardiovascular risk factors. It means blood pressure deserves the same serious monitoring as testosterone levels, hematocrit, PSA, estradiol symptoms, sleep apnea risk, and fertility goals. This guide explains the evidence and the questions to bring to a qualified clinician.

The 2025 FDA Update: Cardiovascular Warning Changed, Blood Pressure Warning Stayed Important

The FDA's 2025 testosterone update made two important points at the same time. First, after reviewing TRAVERSE, the agency recommended removing prior boxed-warning language about increased risk of adverse cardiovascular outcomes for testosterone products used in men with hypogonadism. Second, after reviewing ambulatory blood pressure monitoring studies, FDA required product-specific information and warnings about increased blood pressure across testosterone products.

In plain English: the best large cardiovascular outcomes trial reduced concern that properly prescribed TRT broadly raises major cardiac event risk, but separate blood-pressure studies showed testosterone can still nudge blood pressure upward. Both facts matter.

How Much Can TRT Raise Blood Pressure?

The exact blood-pressure change depends on the product, dose, baseline health, and measurement method. Ambulatory blood pressure monitoring is more informative than a single office reading because it captures blood pressure over many hours during normal daily life. FDA's class-wide conclusion was not that every product raises blood pressure by the same amount, but that increased blood pressure was confirmed with use of testosterone products class-wide.

For an individual patient, even a modest average increase can matter if he already runs high, has sleep apnea, uses stimulants, has kidney disease, carries significant cardiovascular risk, or is close to the threshold where a clinician would diagnose or treat hypertension. A small rise from 116/72 to 120/76 is not the same risk conversation as a rise from 136/84 to 142/88.

Why Testosterone May Affect Blood Pressure

TRT can influence several systems that are relevant to blood pressure. The most discussed pathway is increased red blood cell production. Testosterone can raise hematocrit, which is why guidelines emphasize checking blood counts during therapy. Higher hematocrit does not automatically equal hypertension, but it can increase blood viscosity and becomes a safety concern when levels climb too high.

Testosterone therapy may also affect fluid balance, vascular tone, body composition, sleep apnea severity in susceptible men, and medication interactions. Some men lose visceral fat and improve metabolic markers during well-managed therapy; others experience water retention, worsening snoring, or higher hematocrit. That variability is why monitoring beats guessing.

What TRAVERSE Did and Did Not Prove

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, enrolled 5,246 men ages 45 to 80 with symptoms of hypogonadism, two fasting testosterone levels below 300 ng/dL, and preexisting cardiovascular disease or high cardiovascular risk. Participants received daily transdermal testosterone gel or placebo gel.

The primary endpoint was major adverse cardiac events: cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Testosterone therapy was noninferior to placebo for that endpoint. The trial also observed higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group. That does not prove every TRT user faces those outcomes, but it reinforces the need for individualized risk review rather than casual prescribing.

Who Should Pay Extra Attention to Blood Pressure Before TRT?

Men should be especially careful about blood-pressure monitoring if they already have diagnosed hypertension, borderline readings, kidney disease, diabetes, high coronary calcium, prior cardiovascular events, obstructive sleep apnea, obesity, heavy alcohol use, nicotine use, or stimulant medication use. These factors do not automatically rule out TRT, but they change the risk-benefit discussion.

The Endocrine Society recommends diagnosing hypogonadism only when symptoms and consistently low testosterone levels are both present, and it recommends against starting testosterone in several higher-risk situations, including uncontrolled heart failure, recent myocardial infarction or stroke, elevated hematocrit, untreated severe obstructive sleep apnea, thrombophilia, and near-term fertility plans. Those exclusions are a reminder that TRT is medical therapy, not a generic wellness upgrade.

What to Track at Home

If a clinician clears TRT, home blood pressure tracking can catch changes earlier than occasional office visits. Use a validated upper-arm cuff, sit quietly for several minutes, keep your feet flat, and take readings at consistent times. Many clinicians prefer multiple readings across several days rather than reacting to one high number after caffeine, stress, exercise, or poor sleep.

Useful data to bring to follow-ups includes morning and evening blood pressure logs, resting heart rate, weight changes, snoring or sleep quality changes, ankle swelling, headaches, shortness of breath, chest symptoms, and any changes in medications or supplements. Do not stop or adjust prescribed blood-pressure medication or testosterone dosing without clinician direction.

Labs and Follow-Up That Matter

Blood pressure is not monitored in isolation. A responsible TRT follow-up plan usually includes total testosterone, free testosterone when appropriate, complete blood count with hematocrit and hemoglobin, PSA when indicated, estradiol when symptoms suggest imbalance, metabolic markers, and symptom review. The American Urological Association guideline emphasizes confirming low testosterone with two early-morning measurements and monitoring patients after treatment begins.

Hematocrit is especially relevant because testosterone-induced erythrocytosis is one of the most common safety issues in TRT management. If hematocrit rises too high, a clinician may adjust dose, change delivery method, evaluate sleep apnea or smoking status, pause therapy, or consider other interventions. The right response depends on the patient, not a template.

Questions to Ask a TRT Clinic About Blood Pressure

• Do you require baseline blood pressure readings before prescribing testosterone?
• How do you handle patients with controlled or uncontrolled hypertension?
• Do you review home blood pressure logs after treatment starts?
• How often do you check hematocrit and other cardiovascular risk markers?
• What thresholds trigger dose changes, formulation changes, or referral back to primary care or cardiology?
• Do you screen for sleep apnea symptoms before and during therapy?

Strong clinics should have clear answers. Be cautious with any provider that treats testosterone as a one-lab-number decision, ignores blood pressure, or does not explain what happens if hematocrit or cardiovascular symptoms change.

The Bottom Line

TRT can be appropriate for men with symptoms and repeatedly low testosterone, but blood pressure is no longer a footnote. The FDA's 2025 update clarified that major cardiovascular event risk language changed after TRAVERSE, while blood-pressure warnings became more explicit because ambulatory monitoring studies showed increases across testosterone products.

The practical move is not panic. It is better screening, better home monitoring, better follow-up, and a provider who treats TRT as ongoing medical care. If your blood pressure is already elevated, get it evaluated and controlled with your clinician before assuming testosterone is the next step.

Sources

• FDA: Class-wide labeling changes for testosterone products, February 2025
• NEJM: Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE)
• American Urological Association: Testosterone Deficiency Guideline
• Endocrine Society: Testosterone Therapy for Hypogonadism Guideline Resources